Beijing Leadman Biochemistry Co Ltd
SZSE:300289
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Beijing Leadman Biochemistry Co Ltd
Total Equity
Beijing Leadman Biochemistry Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Beijing Leadman Biochemistry Co Ltd
SZSE:300289
|
Total Equity
¥1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Beigene Ltd
HKEX:6160
|
Total Equity
¥30.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Equity
¥19.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Total Equity
¥3.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Equity
¥9B
|
CAGR 3-Years
51%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Total Equity
¥2.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Leadman Biochemistry Co Ltd
Glance View
Beijing Leadman Biochemistry Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic products. The company is headquartered in Beijing, Beijing and currently employs 522 full-time employees. The company went IPO on 2012-02-16. Its diagnostic reagents include chemiluminescence diagnostic reagents and biochemical diagnostic agents, such as hepatitis B virus attributes and tumor markers. The firm also produces diagnostic instruments and biochemical raw materials. Its diagnostic instruments include automatic luminescence immunity analyzers, among others. Its products are applied in various fields, including liver diseases, kidney diseases, cardiovascular diseases, immunological diseases and diabetes, among others. The firm mainly operates businesses in domestic market.
See Also
What is Beijing Leadman Biochemistry Co Ltd's Total Equity?
Total Equity
1.6B
CNY
Based on the financial report for Dec 31, 2025, Beijing Leadman Biochemistry Co Ltd's Total Equity amounts to 1.6B CNY.
What is Beijing Leadman Biochemistry Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
3%
Over the last year, the Total Equity growth was -1%. The average annual Total Equity growth rates for Beijing Leadman Biochemistry Co Ltd have been -2% over the past three years , 5% over the past five years , and 3% over the past ten years .
